OXIG.L

Oxford Instruments Plc
Oxford Instruments - Sale of Oxford Instruments’ quantum business
10th June 2025, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1656M
Oxford Instruments PLC
10 June 2025
 

This announcement contains inside information

10 June 2025

 

Oxford Instruments plc

Sale of Oxford Instruments' quantum business, NanoScience

Oxford Instruments plc, a leading provider of high technology products and services to industry and scientific research communities, today announces that it has entered into a binding agreement to sell its quantum-focused business Oxford Instruments NanoScience ("NanoScience") to Quantum Design, International Inc. for a £60m total cash consideration ("Sale"), including up to £3m of deferred consideration linked to future revenues from quantum scaling systems.

In FY25, NanoScience generated approximately £59m1 of revenue and £1m1 of adjusted operating profit ("AOP"). Having returned the business to growth and profitability, this Sale crystallises this value for shareholders.

Non-recurring transaction-related costs are expected to be approximately £2m- £3m in FY2025/26. Following the sale, approximately £4m of cost which is currently allocated to the NanoScience business will remain within the Group. We expect to begin to mitigate this in FY2026/27.

The divestment will better enable Oxford Instruments ("the Group") to focus on its remaining businesses, which have growth and margin characteristics that will ensure the Group is better placed to deliver value for shareholders.

Given the strength of the balance sheet, the expected cash proceeds from the sale, and in line with its capital allocation policy, the Group plans to return up to £50 million to shareholders via a share buyback, commencing shortly.

Headquartered in the USA, with a global footprint, Quantum Design offers a range of products and services for scientific, academic and industrial research.

The sale is subject to regulatory approvals and is expected to complete in the third quarter of FY2025/26.

CEO Richard Tyson said:

"The sale of our NanoScience quantum business is in line with our strategy to focus and invest in the best areas of opportunity to grow the Group and create value for shareholders, and supports progress towards our medium-term margin targets. It is also consistent with our focus on our three core markets: materials analysis, semiconductor, and healthcare and life science.

"Quantum Design's desire to lead the business through the next stage of its development and investment journey is a testament to NanoScience's talented team and excellent technology."


LEI: 213800J364EZD6UCE231

 

The person responsible for arranging the release of this announcement on behalf of Oxford Instruments plc is Louise Meads, Interim Company Secretary, Oxford Instruments plc.

Kroll Securities Ltd acted as exclusive financial advisors to Oxford Instruments plc on this transaction. Ashurst LLP were retained as legal counsel.

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Head of Investor Relations                          Stephen.lamacraft@oxinst.com 

 

MHP Group

Katie Hunt/Tim Rowntree/                                                   07710 117517

Veronica Farah                                                                      oxfordinstruments@mhpgroup.com                              

 

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

1 Unaudited figures

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISPKKBKQBKKNAD]]>
TwitterFacebookLinkedIn